Category: ARV

US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices

Source : By Frederick M The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. The near-unanimous decision...

/ 1 June 2017

Access to medicines amendment of the WTO TRIPS Agreement– hype or hope?

By: Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, e.f.m.t.hoen@umcg.nl On 30 January the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome entry into force of...

/ 5 April 2017

The HepC Pill Bill

Source : hepCoalition The HepC Pill Bill-An insight into the availability, pricing and accessibility of HCV treatment Introduction to Direct Acting Antivirals Hepatitis C treatment has remarkably evolved over the years. The previously known standard HCV regimen consisted of a...

/ 5 April 2017

Amendment of the TRIPS Agreement

WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally built into the TRIPS Agreement after...

/ 23 January 2017

WHO Launches New HIV Treatment and Prevention Guidelines

The WHO has made two important new treatment recommendations that will affect all HIV treatment programmes. The recommendations are entitled the ’Early Release’ Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. The recommendations in this...

/ 14 October 2015

Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatment in Morocco

According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management of HCV infection has been hampered...

/ 26 June 2015

Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Suffering from HCV Infection

The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis C Virus (HCV), sofosbuvir, available to...

/ 20 May 2015

The first Middle East and North Africa Community Advisory Board (MENA-CAB)

Casablanca, Morocco, 28 June-01 July 2014 Despite the fact that HIV prevalence in the countries of the Middle East and North Africa is believed to be low at least among the General Population, the rate of increase of new cases...

/ 10 July 2014

Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting

Bangkok, Thailand, February 28, 2014 —Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies....

/ 28 February 2014